JP2019517503A - 遺伝子編集戦略によるhiv−1のネガティブフィードバック調節 - Google Patents
遺伝子編集戦略によるhiv−1のネガティブフィードバック調節 Download PDFInfo
- Publication number
- JP2019517503A JP2019517503A JP2018562997A JP2018562997A JP2019517503A JP 2019517503 A JP2019517503 A JP 2019517503A JP 2018562997 A JP2018562997 A JP 2018562997A JP 2018562997 A JP2018562997 A JP 2018562997A JP 2019517503 A JP2019517503 A JP 2019517503A
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- nucleic acid
- ltr
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345549P | 2016-06-03 | 2016-06-03 | |
US62/345,549 | 2016-06-03 | ||
US201662394334P | 2016-09-14 | 2016-09-14 | |
US62/394,334 | 2016-09-14 | ||
PCT/US2017/034763 WO2017213896A1 (en) | 2016-06-03 | 2017-05-26 | Negative feedback regulation of hiv-1 by gene editing strategy |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019517503A true JP2019517503A (ja) | 2019-06-24 |
Family
ID=60578255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018562997A Pending JP2019517503A (ja) | 2016-06-03 | 2017-05-26 | 遺伝子編集戦略によるhiv−1のネガティブフィードバック調節 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3463290A4 (de) |
JP (1) | JP2019517503A (de) |
CN (1) | CN109640946A (de) |
AU (1) | AU2017277810A1 (de) |
CA (1) | CA3026332A1 (de) |
RU (1) | RU2018144877A (de) |
WO (1) | WO2017213896A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2734621B1 (de) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Beurteilung und verbesserung einer nukleasespaltungsspezifität |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
IL310721A (en) | 2015-10-23 | 2024-04-01 | Harvard College | Nucleobase editors and their uses |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3592853A1 (de) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Unterdrückung von schmerzen durch geneditierung |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
CN110914426A (zh) | 2017-03-23 | 2020-03-24 | 哈佛大学的校长及成员们 | 包含核酸可编程dna结合蛋白的核碱基编辑器 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
AU2018352592A1 (en) | 2017-10-16 | 2020-06-04 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
EP3918071A1 (de) * | 2019-02-01 | 2021-12-08 | Editas Medicine, Inc. | Crispr/cas-verwandte verfahren und zusammensetzungen, die gegen virusgenome gerichtet sind |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
US6576422B1 (en) * | 2000-10-17 | 2003-06-10 | Rohm And Haas Company | Method for identifying products employing gene expression |
ATE527281T1 (de) * | 2004-07-16 | 2011-10-15 | Us Gov Health & Human Serv | Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte |
EP1942192A1 (de) * | 2007-01-08 | 2008-07-09 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Verwendung einer massgeschneiderten Recombinase für die Behandlung einer retroviralen Erkrankung |
PL3138910T3 (pl) * | 2012-12-06 | 2018-01-31 | Sigma Aldrich Co Llc | Oparta na CRISPR modyfikacja i regulacja genomu |
CN106102781A (zh) * | 2013-08-29 | 2016-11-09 | 英联邦高等教育系统天普大学 | 用于hiv感染的rna指导的治疗的方法和组合物 |
JP2017506893A (ja) * | 2014-02-18 | 2017-03-16 | デューク ユニバーシティ | ウイルス複製不活化組成物並びにその製造方法及び使用 |
WO2016086177A2 (en) * | 2014-11-25 | 2016-06-02 | Drexel University | Compositions and methods for hiv quasi-species excision from hiv-1-infected patients |
MA41382A (fr) * | 2015-03-20 | 2017-11-28 | Univ Temple | Édition génique basée sur le système crispr/endonucléase à induction par tat |
-
2017
- 2017-05-26 JP JP2018562997A patent/JP2019517503A/ja active Pending
- 2017-05-26 EP EP17810720.7A patent/EP3463290A4/de not_active Withdrawn
- 2017-05-26 AU AU2017277810A patent/AU2017277810A1/en not_active Abandoned
- 2017-05-26 WO PCT/US2017/034763 patent/WO2017213896A1/en unknown
- 2017-05-26 CN CN201780048467.5A patent/CN109640946A/zh active Pending
- 2017-05-26 CA CA3026332A patent/CA3026332A1/en not_active Abandoned
- 2017-05-26 RU RU2018144877A patent/RU2018144877A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2017213896A1 (en) | 2017-12-14 |
AU2017277810A2 (en) | 2019-01-03 |
CN109640946A (zh) | 2019-04-16 |
AU2017277810A1 (en) | 2018-12-06 |
EP3463290A4 (de) | 2019-10-30 |
CA3026332A1 (en) | 2017-12-14 |
RU2018144877A (ru) | 2020-07-09 |
EP3463290A1 (de) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019517503A (ja) | 遺伝子編集戦略によるhiv−1のネガティブフィードバック調節 | |
US20200392487A1 (en) | Excision of retroviral nucleic acid sequences | |
US20230193257A1 (en) | Tat-induced crispr/endonuclease-based gene editing | |
US20230287401A1 (en) | Rna guided compositions for preventing and treating hepatitis b virus infections | |
AU2016270702B2 (en) | Methods and compositions for RNA-guided treatment of HIV infection | |
US20190367910A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
US20190083656A1 (en) | Methods and compositions utilizing cpf1 for rna-guided gene editing | |
US20200140865A1 (en) | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents | |
US20190085326A1 (en) | Negative feedback regulation of HIV-1 by gene editing strategy | |
US20210060138A1 (en) | CRISPR and LASER ART Eliminates HIV | |
WO2022256516A2 (en) | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190208 |